Cocrystal Pharma, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
COCP$1.11+6.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
| Three months ended June 30, | Six months ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue and grant income: | ||||
| Government contract revenue | 105 | - | 330 | - |
| Operating expenses: | ||||
| Research and development | 2,142 | 1,122 | 3,513 | 2,482 |
| General and administrative | 1,147 | 986 | 2,357 | 1,967 |
| Total operating expenses | 3,289 | 2,108 | 5,870 | 4,449 |
| Loss from operations | (3,184) | (2,108) | (5,540) | (4,449) |
| Other income (expense): | ||||
| Interest income, net | 10 | 28 | 32 | 65 |
| Foreign exchange gain (loss) | 10 | 25 | 45 | 28 |
| Total other income, net | 20 | 53 | 77 | 93 |
| Net loss | $(3,164) | $(2,055) | (5,463) | (4,356) |
| Net loss per common share, basic and diluted | $(0.23) | $(0.20) | (0.40) | (0.43) |
| Weighted average number of common shares outstanding, basic and diluted | 13,788 | 10,174 | 13,787 | 10,174 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.